{"id":"mn-rgp120-hiv-1-and-a244-rgp120-hiv-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Systemic reactions (fever, fatigue, myalgia)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These vaccines present recombinant gp120 proteins from different HIV-1 strains (MN and A244) to stimulate both humoral and cellular immune responses against the envelope glycoprotein. By targeting gp120, a critical component of HIV's entry mechanism, the vaccines aim to generate neutralizing antibodies and T-cell responses that can prevent or control HIV-1 infection.","oneSentence":"MN rgp120/HIV-1 and A244 rgp120/HIV-1 are recombinant HIV envelope protein vaccines designed to elicit immune responses against the gp120 surface antigen of HIV-1.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:59.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 prevention in seronegative adults"}]},"trialDetails":[{"nctId":"NCT00001096","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00000871","phase":"PHASE2","title":"A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00006327","phase":"PHASE3","title":"Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand","status":"COMPLETED","sponsor":"VaxGen","startDate":"1999-03","conditions":"HIV Infections, HIV Seronegativity","enrollment":2500},{"nctId":"NCT00002402","phase":"PHASE1","title":"A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines","status":"COMPLETED","sponsor":"VaxGen","startDate":"","conditions":"HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MN rgp120/HIV-1 and A244 rgp120/HIV-1","genericName":"MN rgp120/HIV-1 and A244 rgp120/HIV-1","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"MN rgp120/HIV-1 and A244 rgp120/HIV-1 are recombinant HIV envelope protein vaccines designed to elicit immune responses against the gp120 surface antigen of HIV-1. Used for HIV-1 prevention in seronegative adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}